



Stereospecific ligands and their complexes. Part XV. Synthesis, characterization and cytotoxicity of novel platinum(IV) complexes with some esters of ethylenediamine-*N,N'*-di-*S,S*-(2,2'-dibenzyl)acetic acid. Crystal structure of *O,O'*-dipropyl-ethylenediamine-*N,N'*-di-*S,S*-(2,2'-dibenzyl)acetate dihydrochloride [☆]

Dejana P. Dimitrijević^a, Verica V. Glođović^a, Gordana P. Radić^a, Santiago García-Granda^b, Laura Menéndez-Taboada^b, Marija Milovanović^c, Vladislav Volarević^c, Nebojša Arsenijević^c, Goran A. Bogdanović^d, Srećko R. Trifunović^{a,*}

^a Department of Chemistry, Faculty of Science, University of Kragujevac, Radoja Domanovića 12, 34000 Kragujevac, Serbia

^b Faculty of Chemistry, University of Oviedo, Spain

^c Centre for Molecular Medicine and Stem Cell Research, Faculty of Medical Science, University of Kragujevac, Svetozara Markovića 69, 34000 Kragujevac, Serbia

^d VINČA Institute of Nuclear Sciences, Laboratory of Theoretical Physics and Condensed Matter Physics, University of Belgrade, P.O. Box 522, 11001 Belgrade, Serbia

ARTICLE INFO

Article history:

Received 19 July 2012

Received in revised form 18 March 2013

Accepted 24 March 2013

Available online 2 April 2013

Keywords:

Platinum(IV) complexes

Cytotoxicity

X-ray diffraction

Infrared spectra

NMR spectra

ABSTRACT

The synthesis of ethylenediamine-*N,N'*-di-*S,S*-(2,2'-dibenzyl)acetic acid ($H_2\text{-}S,S\text{-eddba}$) and its ethyl-, propyl-, butyl-esters ($R_2\text{-}S,S\text{-eddba}$) are reported here. The esters were used for synthesis of the corresponding platinum(IV) complexes, $[\text{PtCl}_4(R_2\text{-}S,S\text{-eddba})]$. The compounds were characterized by elemental analysis, infrared, ^1H and ^{13}C NMR spectroscopy. The structure of propyl ester of $H_2\text{-}S,S\text{-eddba}$ was confirmed by single-crystal X-ray analysis. All $[\text{PtCl}_4(R_2\text{-}S,S\text{-eddba})]$ complexes displayed significantly higher *in vitro* cytotoxicity in comparison to cisplatin.

© 2013 Published by Elsevier B.V.

1. Introduction

Platinum(II/IV) and other metal complexes have attracted a great attention as chemotherapeutic drugs mostly against cancer [1,2]. Investigations in this field have stimulated successful application of cisplatin in treatment of various types of human cancer [3]. The high nephrotoxicity and neurotoxicity seriously limit the cisplatin usage. Faced with these problems in clinical usage, numerous novel platinum complexes have been synthesized and tested with respect to their anticancer activity [1–7].

Although a lot of platinum complexes have been prepared and tested as antitumor reagents, just a few of them have been included in clinical use, such as carboplatin. Compared with cisplatin, carboplatin should be used in much higher doses

[1,8,9]. Taking in consideration the mentioned problems, considerable progress in platinum chemistry concerning the synthesis of kinetically inert platinum(IV) compounds was made, like JM216 (*cis,trans,cis*- $[\text{PtCl}_2(\text{CH}_3\text{COO})_2(\text{NH}_3)\{\text{NH}_2(\text{C}_6\text{H}_{11})\}]$, configuration index OC-6-32) with an octahedral coordination sphere [10]. These complexes are much more inert than similar platinum(II) complexes and can therefore be administered orally [9–12]. The kinetic inertness of the platinum(IV) complexes also offers the advantage of reduced side-reactions *in vivo* and a significant decrease in drug loss through reactions with plasma proteins or other low molecular weight biomolecules should be expected.

Recently, some Pt(II/IV) complexes with linear O–N–N–O edda-type (edda = ethylenediamine-*N,N'*-diacetate ion) ligands: ethylenediamine-*N,N'*-di-*(S,S)*-2-propanoate (*S,S*-eddp) [7,12], ethylenediamine-*N,N'*-di-3-propanoate (eddp) and 1,3-propylenediamine-*N,N'*-diacetate (1,3-pdda) [13] have been prepared and their *in vitro* antitumor activity has been tested. Also, the *in vitro* antitumor activity of platinum(II/IV) complexes with methylene modified cyclohexyl ethylenediamine-*N,N'*-diacetate [14], *O,O'*-dialkyl esters of (*S,S*)-ethylenediamine-*N,N'*-di-2-(4-methyl)

[☆] Part XIV J.M. Vujić, S. García-Granda, L. Menéndez-Taboada, S.V. Novaković and S.R. Trifunović, J. Seb. Chem. Soc. 77 (2012) 1–11.

* Corresponding author. Tel.: +381 34300263; fax: +381 335040.

E-mail address: srecko@kg.ac.rs (S.R. Trifunović).

